Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs
Renal impairment may have a significant impact on the pharmacokinetics of drugs. Ad hoc studies in subjects with renal impairment are required by the regulatory authorities to propose dose adjustments in these subjects, to find a dosing regimen able to provide a systemic exposure similar to those in subjects with a normal renal function given the relevant clinical dose.
To evaluate the main descriptors and establish a predictive model of the effect of renal impairment on the exposure of new drugs, we considered 73 marketed drugs, for which studies in subjects with different degrees of renal impairment were available in the literature. Multivariate analysis was performed using the main pharmacokinetic parameters. Other approaches, including data mining and machine learning techniques, were tested to propose models based on a categorical definition of the exposure changes.
Stepwise multivariate regression analyses revealed, as expected, that the fraction of dose excreted unchanged in urine and plasma protein binding were the factors primarily related to the change in exposure between subjects with normal and impaired renal function. Data mining techniques provided similar results.
The pharmacokinetic predictions were however not always satisfactory, especially for drugs which, despite the negligible renal excretion, are characterized by significant increases in the systemic exposure in subjects with renal impairment. This phenomenon, interpreted considering the accumulation of endogenous metabolism inhibitors in subjects with moderate and severe renal disease (uremic toxins), cannot be fully captured and described, likely owing to an incomplete understanding of the pathophysiological phenomena and to some limitations of the available database of clinical studies.
Compliance with Ethical Standards
No external funding was used in the preparation of this article.
Conflict of Interest
Elisa Borella and Paolo Magni have no conflicts of interest directly relevant to the content of this article. Italo Poggesi is an employee at Janssen R&D.
- 10.US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labeling. Draft FDA guidance. 2010. http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. Accessed 20 Mar 2017.
- 11.US National Library of Medicine. DailyMed. Bethesda (MD): U.S. National Library of Medicine, National Institutes of Health, Health and Human Services; 2005. http://purl.access.gpo.gov/GPO/LPS81632. Accessed 20 Mar 2017.
- 25.Bastien P, Tenenhaus M. PLS regression and multiple imputations. In: Vilares M, et al. (eds), Proceedings of the PLS’03 international symposium. Paris: CISIA; 2003: pp. 497–8. http://pdfs.semanticscholar.org/a547/464f9e10a6101a5e75ba5504fe9e2cc905b0.pdf. Accessed 22 Jun 2017.
- 27.Preda C, Saporta G, Hedi M, et al. The NIPALS algorithm for missing functional data. Rom J Pure Appl Math. 2010;55(4):315–26. http://cedric.cnam.fr/fichiers/art_2223.pdf. Accessed 20 Mar 2017.
- 28.R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org/. Accessed 20 Mar 2017.
- 29.Fung G. A comprehensive overview of basic clustering algorithms. 2001. http://pdfs.semanticscholar.org/b7cd/0a4e0a129b55b76b7a0faf8ec73a5ebd1645.pdf. Accessed 20 Mar 2017.
- 30.Demsar J, Curk T, Erjavec A, et al. Orange: data mining toolbox in Python. J Mach Learn Res. 2013;14:2349–53.Google Scholar
- 39.Hsu V, de L T Vieira M, Zhao P, et al. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet. 2014;53(3):283–93.CrossRefPubMedGoogle Scholar
- 40.Lu C, Suri A, Shyu WC, et al. Assessment of cytochrome P450-mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. Biopharm Drug Dispos. 2014;35(9):543–52.CrossRefPubMedGoogle Scholar
- 41.Grillo JA, Zhao P, Bullock J, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos. 2012;33(2):99–110.CrossRefPubMedGoogle Scholar